Q32 Bio Inc.
(NASDAQ:QTTB) stock is trading higher on Monday after the clinical-stage biotechnology company shared positive 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial.
The data showed that bempikibart produced clinically meaningful hair regrowth in patients with severe or very severe alopecia areata while maintaining a favorable safety profile.
The company said the data support advancing the antibody into a registration-directed program during the first half of 2027.
Read Also: Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains Hair Regrowth Seen Across Multiple Efficacy Measures Part B enrolled 33 patients with baseline Severity of Alopecia Tool (SALT) scores between 50 and 100, including individuals previously treated with oral JAK inhibitors.
